185 related articles for article (PubMed ID: 11890365)
1. ISIS-3521. Isis Pharmaceuticals.
Li K; Zhang J
Curr Opin Investig Drugs; 2001 Oct; 2(10):1454-61. PubMed ID: 11890365
[TBL] [Abstract][Full Text] [Related]
2. Alicaforsen. Isis Pharmaceuticals.
Gewirtz AT; Sitaraman S
Curr Opin Investig Drugs; 2001 Oct; 2(10):1401-6. PubMed ID: 11890355
[TBL] [Abstract][Full Text] [Related]
3. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.
Cunningham CC; Holmlund JT; Schiller JH; Geary RS; Kwoh TJ; Dorr A; Nemunaitis J
Clin Cancer Res; 2000 May; 6(5):1626-31. PubMed ID: 10815879
[TBL] [Abstract][Full Text] [Related]
5. Technology evaluation: alicaforsen (Isis).
Gewirtz AT; Sitaraman SV
Curr Opin Mol Ther; 2005 Jun; 7(3):273-81. PubMed ID: 15977426
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
7. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
8. Technology evaluation: ISIS-3521.
Li K; Zhang J; Sirois P; Hu Y
Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
[TBL] [Abstract][Full Text] [Related]
9. GTI-2040. Lorus Therapeutics.
Orr RM
Curr Opin Investig Drugs; 2001 Oct; 2(10):1462-6. PubMed ID: 11890366
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol. National Cancer Institute.
Wang HK
Curr Opin Investig Drugs; 2001 Aug; 2(8):1149-55. PubMed ID: 11892928
[TBL] [Abstract][Full Text] [Related]
11. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
12. Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study.
Cripps MC; Figueredo AT; Oza AM; Taylor MJ; Fields AL; Holmlund JT; McIntosh LW; Geary RS; Eisenhauer EA
Clin Cancer Res; 2002 Jul; 8(7):2188-92. PubMed ID: 12114419
[TBL] [Abstract][Full Text] [Related]
13. AEG-35156, an antisense oligonucleotide against X-linked inhibitor of apoptosis for the potential treatment of cancer.
Tamm I
Curr Opin Investig Drugs; 2008 Jun; 9(6):638-46. PubMed ID: 18516763
[TBL] [Abstract][Full Text] [Related]
14. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
15. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
O'Dwyer PJ; Stevenson JP; Gallagher M; Cassella A; Vasilevskaya I; Monia BP; Holmlund J; Dorr FA; Yao KS
Clin Cancer Res; 1999 Dec; 5(12):3977-82. PubMed ID: 10632328
[TBL] [Abstract][Full Text] [Related]
16. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
Coudert B; Anthoney A; Fiedler W; Droz JP; Dieras V; Borner M; Smyth JF; Morant R; de Vries MJ; Roelvink M; Fumoleau P;
Eur J Cancer; 2001 Nov; 37(17):2194-8. PubMed ID: 11677106
[TBL] [Abstract][Full Text] [Related]
18. Imatinib. Novartis.
Radford IR
Curr Opin Investig Drugs; 2002 Mar; 3(3):492-9. PubMed ID: 12054102
[TBL] [Abstract][Full Text] [Related]
19. Technology evaluation: CpG-7909, Coley.
Paul S
Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
[TBL] [Abstract][Full Text] [Related]
20. Drug evaluation: OGX-011, a clusterin-inhibiting antisense oligonucleotide.
Schmitz G
Curr Opin Mol Ther; 2006 Dec; 8(6):547-54. PubMed ID: 17243491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
